These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27309261)

  • 1. Serum lactate dehydrogenase is a predictor of poor survival in malignant melanoma.
    Gao D; Ma X
    Panminerva Med; 2017 Dec; 59(4):332-337. PubMed ID: 27309261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic score for patients with advanced melanoma treated with ipilimumab.
    Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
    Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress.
    Desch A; Gebhardt C; Utikal J; Schneider SW
    Int J Cancer; 2017 Feb; 140(4):914-921. PubMed ID: 27813063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
    Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
    Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma.
    Bánfalvi T; Boldizsár M; Gergye M; Gilde K; Kremmer T; Ottó S
    Pathol Oncol Res; 2002; 8(3):183-7. PubMed ID: 12515998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
    Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H
    Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma.
    Wevers KP; Kruijff S; Speijers MJ; Bastiaannet E; Muller Kobold AC; Hoekstra HJ
    Ann Surg Oncol; 2013 Aug; 20(8):2772-9. PubMed ID: 23512078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis.
    Petrelli F; Ardito R; Merelli B; Lonati V; Cabiddu M; Seghezzi S; Barni S; Ghidini A
    Melanoma Res; 2019 Feb; 29(1):1-12. PubMed ID: 30308577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single-institution validation of the AJCC staging system for stage IV melanoma.
    Neuman HB; Patel A; Ishill N; Hanlon C; Brady MS; Halpern AC; Houghton A; Coit DG
    Ann Surg Oncol; 2008 Jul; 15(7):2034-41. PubMed ID: 18465172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.
    Diem S; Kasenda B; Spain L; Martin-Liberal J; Marconcini R; Gore M; Larkin J
    Br J Cancer; 2016 Feb; 114(3):256-61. PubMed ID: 26794281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma.
    Hoejberg L; Bastholt L; Johansen JS; Christensen IJ; Gehl J; Schmidt H
    Melanoma Res; 2012 Aug; 22(4):287-93. PubMed ID: 22617301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
    Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
    Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV Melanoma.
    Weide B; Schäfer T; Martens A; Kuzkina A; Uder L; Noor S; Garbe C; Harter PN; Mittelbronn M; Wischhusen J
    J Invest Dermatol; 2016 Dec; 136(12):2444-2452. PubMed ID: 27705749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
    Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
    Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L.
    Liu R; Cao J; Gao X; Zhang J; Wang L; Wang B; Guo L; Hu X; Wang Z
    Tumour Biol; 2016 Oct; 37(10):14083-14088. PubMed ID: 27511116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
    Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
    Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse.
    Egberts F; Hitschler WN; Weichenthal M; Hauschild A
    Melanoma Res; 2009 Feb; 19(1):31-5. PubMed ID: 19104452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of serum lactate dehydrogenase and prognosis for osteosarcoma.
    Fu Y; Lan T; Cai H; Lu A; Yu W
    Medicine (Baltimore); 2018 May; 97(19):e0741. PubMed ID: 29742740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.
    Deichmann M; Benner A; Bock M; Jäckel A; Uhl K; Waldmann V; Näher H
    J Clin Oncol; 1999 Jun; 17(6):1891-6. PubMed ID: 10561230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.